(1 - 7 von 7
)
Novartis' ACZ885 Helps Reduce Steroid Use In 45% Of Childhood...
www.finanznachrichten.de
Dr Nico Wulffraat, one of the study investigators and pediatric immunologist at Wilhelmina Children's Hospital, University Medical Center in ...
JIA: Absetzen von MTX nach sechs vs 12 Monaten bei Kindern in...
www.rheuma-online.de
Dirk Foell, MD; Nico Wulffraat, MD; Lucy R. Wedderburn, MD, PhD; Helmut Wittkowski, MD; Michael Frosch, MD; Joachim Gerß, PhD; Valda Stanevicha, MD; ...
Novartis International AG: Novartis Phase III study shows ACZ
www.finanznachrichten.de
Novartis International AG /
Novartis Phase III study shows ACZ885 helped substantially reduce steroid use in 45% of patients with serious form of childhood...
Randomisierte Studie mit Tocilizumab bei systemischer juveniler...
www.rheuma-online.de
... M.D., Rosa Merino, M.D., Rik Joos, M.D., Alexei Grom, M.D., Ph.D., Nico Wulffraat, M.D., Zbigniew Zuber, M.D., Francesco Zulian, M.D., Daniel Lovell, ...
Novartis’ SJIA study meets endpoints - Pf Media
pf-media.co.uk
... on this young population,” said Dr Nico Wulffraat, one of the study investigators and pediatric immunologist at Wilhelmina Children's Hospital, ...
Paediatric rheumatology expert group meetingwww.ema.europa.eu › events › paediatric-rheumatol...
www.ema.europa.eu
· ... PHARMacovigilance for Adverse effects in Childhood arthritis focusing on Immune modulatory drugs, Dr Nico Wulffraat (PDF KB).
Population Imaging » News
populationimaging.eu
Dr. Nico Wulffraat, department of Child Immunology of the UMC Utrecht, receives € 3 million for the project PHARMACHILD (Long-term PHARMacovigilance for ...
sortiert nach Relevanz / Datum